Cited by 616Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Open access
Lanoiselée, Hélène-Marie, Nicolas, Gaël, Wallon, David, Rovelet-Lecrux, Anne, Lacour, Morgane, Rousseau, Stéphane, Richard, Anne-Claire, Pasquier, Florence +29 more·2017·PLOS Medicine

Abstract

BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002270

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mutations in PS1 and PS2 primarily alter APP γ-cleavage, resulting in a decreased Aβ40/42 ratio.

    “Mutations in PS1 and PS2 primarily alter APP γ-cleavage, thereby resulting in a decreased Aβ40/42 ratio.”
  • De novo variants in APP, PSEN1, and PSEN2 have been identified by sequencing in sporadic cases of EOAD that occur with no family history of disease.

    “Although causal variants in these genes are typically thought to be inherited in an autosomal dominant fashion, de novo variants in APP, PSEN1, and PSEN2 have also been identified by sequencing in sporadic cases of EOAD that occur with no family history of disease [158, 159].”

    From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [158]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., Rouaud, O., Ceccaldi, M., Félician, O., Godefroy, O., Formaglio, M., Croisile, B., Auriacombe, S., Chamard, L., Vincent, J.-L., Sauvée, M., Marelli-Tosi, C., Gabelle, A., Ozsancak, C., Pariente, J., Paquet, C., Hannequin, D., Campion, D., & collaborators of the CNR-MAJ project
Affiliations
  • Inserm (FR)
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Centre Hospitalier Sainte-Anne (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • CHU Dijon Bourgogne (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Hospices Civils de Lyon (FR)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Centre Hospitalier Universitaire de Grenoble (FR)
  • Centre Hospitalier Universitaire de Montpellier (FR)
  • Centre Hospitalier Universitaire de Toulouse (FR)
Corresponding author
Campion, Dominique
Venue
PLOS Medicine
Published
2017-03-28
Volume
14
Issue
3
Pages
e1002270
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2600872530
Cited by
616
References
44
Citations by year
2026: 58 · 2025: 102 · 2024: 94 · 2023: 75 · 2022: 79 · 2021: 64 · 2020: 58 · 2019: 41 · 2018: 34 · 2017: 9
FWCI
28.74
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
Funders
  • Clinical Research Hospital Program from the French Ministry of Health (GMAJ 2008/067)
  • French Ministry of Health (CNR-MAJ)
  • European Union (JPND PERADES, ANR-13-JPRF-0001-04)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
early-onset Alzheimer's disease, APP mutations, PSEN1 mutations, PSEN2 mutations, presenilin, amyloid precursor protein, novel mutations, de novo mutations, sporadic Alzheimer's disease, familial Alzheimer's disease, genetic screening, variant interpretation, cerebrospinal fluid biomarkers, total tau, phosphorylated tau, amyloid-beta 42, genetic counseling, mutation carriers
MeSH terms
Adult, Alzheimer Disease, Female, France, Genetic Testing, Humans, Male, Middle Aged, Mutation, Amyloid beta-Protein Precursor, Age of Onset, Presenilin-1, Presenilin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review